Stock Information Data is 15 minutes delayed
ContraFect Corporation — Common Stock
Nasdaq: CFRX
Price
Change
Market Cap
Volume
Company Overview
ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa.
Officers & Directors
Roger J. Pomerantz, M.D., F.A.C.P.
President, Chief Executive Officer and Chairman of the Board
Dr. Pomerantz was appointed ContraFect’s President, Chief Executive Officer and Chairman of the board of directors in April of 2019, prior to which he served as Vice Chairman of the Company’s board of directors sinc...
View Full Profile »
Cara Cassino, M.D.
Chief Medical Officer and Executive Vice President of Research and Development
Dr. Cassino has over 20 years of experience as a clinician and executive in healthcare, including over 14 years of experience in pharmaceutical product development and over 20 successful regulatory submissions in the US and glo...
View Full Profile »
Michael Messinger, CPA
Chief Financial Officer
Mr. Messinger has more than 15 years of experience in finance, accounting and forecasting for clinical development. He served as Controller of Coelacanth Corporation prior to his role as Director of Finance for Lexicon Pharmace...
View Full Profile »
Nancy Dong
VP, Finance & Administration
Ms. Dong has more than 20 years of experience in accounting, strategic planning, budgeting and forecasting, organizational development, financial systems and controls. She served as controller at XL Marketing and Alley Corp pri...
View Full Profile »
Natalie Bogdanos
General Counsel, Corporate Secretary & Data Protection Officer
Ms. Bogdanos has more than 20 years of in-depth legal experience, across many areas of law including contract, intellectual property, licensing, regulatory, corporate governance, securities, litigation and data privacy. 14 of t...
View Full Profile »
Roger J. Pomerantz, M.D., F.A.C.P.
President, Chief Executive Officer and Chairman of the Board
Dr. Pomerantz was appointed ContraFect’s President, Chief Executive Officer and Chairman of the board of directors in April of 2019, prior to which he served as Vice Chairman of the Company’s board of directors sinc...
View Full Profile »
Sol Barer, Ph.D.
Lead Director
Dr. Barer joined Celanese Research Company in 1974 and formed the Biotechnology Group that was spun out to form Celgene. Dr. Barer was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and served as Exec...
View Full Profile »
Steven C. Gilman, Ph.D.
Vice Chairman of the Board
Dr. Gilman has served on the board of directors since May 2015. He was Chief Executive Officer and Chairman of the board of directors from May 2015 until April 2019. Prior to ContraFect, he served as the Executive Vice Presiden...
View Full Profile »
Cary W. Sucoff
Director
Mr. Sucoff has served as a member of our board of directors since May 2010. Mr. Sucoff has more than 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. He has participated i...
View Full Profile »
David N. Low, Jr.
Director
Mr. Low has served as a member of our board of directors since April 2014. Mr. Low has worked as an investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical tec...
View Full Profile »
Michael J. Otto, Ph.D.
Director
Dr. Otto has served as a member of our board of directors since April 2014. Most recently, he was Chief Scientific Officer of Pharmasset from October 1999 until February 2012, when the company was acquired by Gilead Sciences. H...
View Full Profile »
Lishan Aklog, M.D.
Director
Dr. Aklog is Co-Founder, Chairman and Chief Executive Officer of PAVmed Inc. (Nasdaq: PAVM). Dr. Aklog has served as Executive Chairman of Lucid Diagnostics Inc. since its inception in 2018, as a co-founding Partner of both Pav...
View Full Profile »Annaliesa Anderson, PhD, FAAM
Science & Technology Committee Observer
Dr. Anderson is an Observer on our Science & Technology Committee. She has over 20 years of pharmaceutical research and development experience and is currently the Vice President and Chief Scientific Officer for Bacte...
View Full Profile »